Beth Hecht - 31 Jan 2023 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role: Chief Legal Officer and Corporate Secretary
Signature: /s/ Beth Hecht
Issuer symbol: XERS
Transactions as of: 31 Jan 2023
Net transactions value: $0
Form type: 4
Filing time: 01 Feb 2023, 15:12:19 UTC
Previous filing: 24 Jun 2022
Next filing: 15 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	XERS	Common Stock	Award	$0	+350,000	+78%	$0.000000	797,758	31 Jan 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years.
F2	These shares include 5,039 shares that were purchased on June 30, 2022 and 5,898 shares that were purchased on December 31, 2022 due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan.

Remarks:

Chief Legal Officer and Corporate Secretary